专题:Pharmaceutical industry and healthcare

This cluster of papers explores the impact of pharmaceutical industry sponsorship on research outcome and quality, including conflicts of interest, financial ties between physicians and industry, direct-to-consumer advertising, publication bias, and ethical considerations in medical practice. The papers investigate the influence of funding sources on clinical trials, prescribing behavior, and the integrity of medical science.
最新文献
How Addiction Psychiatrists Add Value to (Mental) Health Care in Canada

article Full Text OpenAlex

Health and medical researchers are willing to trade their results for journal impact factors: results from a discrete choice experiment

article Full Text OpenAlex

Enter the Spiral: The Adverse Consequences of Professional and Lay Expertise for Sufferers’ Lived Experiences

book-chapter Full Text OpenAlex

Impact of China’s National Drug Price Negotiation Policy on Availability, Affordability, and Regional Equity of Negotiated Drugs: A Multidimensional Nationwide Analysis, 2018 to 2021

article Full Text OpenAlex

Unequal contributions in global allergy research: A comparative study of high-, low-, and middle-income countries

article Full Text OpenAlex

How Increasing Research Demands Threaten Equity in Dermatology Residency Selection and Strategies for Reform

article Full Text OpenAlex

An Observational Study of Nicotine Replacement Therapy Availability Through Pharmacist Prescribing in the California Central Valley

article Full Text OpenAlex

Evaluation of the safety profile of prolonged-release EE/DNG oral contraceptives: a critical appraisal

review Full Text OpenAlex

The UK must defend drug price controls

editorial Full Text OpenAlex

Medical Policy Reform in the Digital Age: Responding to Health Crises Shaped by Internet Public Opinion

review Full Text OpenAlex

近5年高被引文献
Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update

article Full Text OpenAlex 239 FWCI54.97673351

Responsible Conduct of Research

book Full Text OpenAlex 205 FWCI61.58132846

Impact of Patient Engagement on Healthcare Quality: A Scoping Review

review Full Text OpenAlex 158 FWCI57.1952776

Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets

paratext Full Text OpenAlex 134 FWCI0

Medication Without Harm

article Full Text OpenAlex 126 FWCI18.43095884

Conceptualising commercial entities in public health: beyond unhealthy commodities and transnational corporations

review Full Text OpenAlex 100 FWCI47.82019696

Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes

article Full Text OpenAlex 94 FWCI57.82453886

Trends in Prescription Drug Launch Prices, 2008-2021

article Full Text OpenAlex 92 FWCI21.2467528

Disclosing and managing non-financial conflicts of interest in scientific publications

article Full Text OpenAlex 91 FWCI31.64560858

Corporate Political Activity: Taxonomies and Model of Corporate Influence on Public Policy

article Full Text OpenAlex 86 FWCI40.31898959